Literature DB >> 2449429

A change in apolipoprotein B expression is required for the binding of apolipoprotein E to very low density lipoprotein.

Y Ishikawa1, C J Fielding, P E Fielding.   

Abstract

Factors affecting the association of apolipoprotein E (apoE) with human plasma very low density lipoprotein (VLDL) were investigated in experiments in which the lipid content of the lipoprotein was modified either by lipid transfer in the absence of lipolysis or through the action of lipoprotein lipase. In both cases, lipoprotein particles initially containing no apoE (VLDL-E), isolated by heparin affinity chromatography, were modified until they had the same lipid composition as native apoE-containing VLDL (VLDL+E) from the same plasma. Transfer-modified lipoproteins, unlike native VLDL+E, did not bind apoE or interact with heparin. In contrast, VLDL-E, whose lipid composition was modified to the same extent by lipase, bound apoE and bound to heparin under the same conditions as native VLDL+E. A structural protein (apolipoprotein B) epitope characteristic of VLDL+E was expressed during lipolysis prior to ApoE or heparin binding. The data suggest that the reaction of apoE with VLDL-E is a two-step reaction. The appearance of apoB is modified during lipolysis, with expression of a major heparin-binding site. The modified VLDL then becomes competent to bind apoE. The lipid composition of VLDL appears not to be a major factor in the ability of VLDL to bind apoE or to bind to heparin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449429

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Modulation of apolipoprotein E-mediated plasma clearance and cell uptake of emulsion particles by cholesteryl ester.

Authors:  H Saito; K Okuhira; N Tsuchimoto; A Vertut-Doi; C Matsumoto; T Tanimoto; S Okada; T Handa
Journal:  Lipids       Date:  2001-01       Impact factor: 1.880

2.  Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.

Authors:  N S Shachter; T Hayek; T Leff; J D Smith; D W Rosenberg; A Walsh; R Ramakrishnan; I J Goldberg; H N Ginsberg; J L Breslow
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

3.  Nonuniform radiolabeling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B.

Authors:  R Ramakrishnan; Y Arad; S Wong; H N Ginsberg
Journal:  J Lipid Res       Date:  1990-06       Impact factor: 5.922

4.  Function and comorbidities of apolipoprotein e in Alzheimer's disease.

Authors:  Valérie Leduc; Dorothée Domenger; Louis De Beaumont; Daphnée Lalonde; Stéphanie Bélanger-Jasmin; Judes Poirier
Journal:  Int J Alzheimers Dis       Date:  2011-04-05

5.  Replacement of cysteine at position 46 in the first cysteine-rich repeat of the LDL receptor impairs apolipoprotein recognition.

Authors:  A Benito-Vicente; K B Uribe; H Siddiqi; S Jebari; U Galicia-Garcia; A Larrea-Sebal; A Cenarro; M Stef; H Ostolaza; F Civeira; L Palacios; C Martin
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.